PAREXEL Introduces Its Connected Journey™ of Newly Integrated Data-Driven Services to Simplify Drug Development & Commercia...
June 19 2017 - 08:00AM
Business Wire
Features new ForeSite™ clinical trial
methodology designed to reliably predict site success
As life science companies increasingly seek to gain insights
from diverse data sources to make drug development more efficient
and effective, PAREXEL International Corporation (NASDAQ: PRXL), a
leading global biopharmaceutical services provider, is launching
its Connected Journey™ of data-driven services. This newly
integrated network, powered by PAREXEL® Analytics capabilities,
combines PAREXEL’s technology, processes, and expertise to deliver
critical intelligence supporting clinical development and
commercialization.
PAREXEL is focused on expediting activities such as protocol
design, study start-up, trial execution, regulatory submission, and
product commercialization. By integrating its data-driven services,
PAREXEL has accelerated a number of key processes. These processes
include moving more rapidly from final protocol available to last
site initiated, accelerating site activation, and achieving faster
turnaround times from database lock to clinical study report1. As a
result, PAREXEL is helping biopharmaceutical clients complete
clinical trials 22 percent faster than the industry average2.
PAREXEL’s Connected Journey consists of more than 40 innovative
data-driven services. Its most recent innovation, the ForeSite™
clinical trial methodology, integrates therapeutic area expertise,
real-time analytics technology, and centralized oversight to more
reliably predict site productivity. The solution enables sponsors
to optimize feasibility and site and country selection, as well as
to more effectively engage and retain sites and patients.
“While drug companies have access to more data sources than ever
before, they face challenges in generating and integrating
meaningful insights that drive timely and actionable decisions,”
said Mark A. Goldberg, M.D., President and Chief Operating Officer,
PAREXEL. “Aggregating and leveraging the right data to drive value
requires a broad range of services working together to generate
insights across the entire drug development and commercialization
spectrum. We believe PAREXEL’s global scale and broad technical
expertise offer clients a uniquely integrated and comprehensive
portfolio — delivered by a single provider.”
“The data resources to inform decision making are available, but
to yield true value they must all be brought together,” said Xavier
Flinois, President, PAREXEL Informatics. “PAREXEL’s Connected
Journey moves from single solutions to the industry’s largest
system of interrelated data-driven innovations. This model
seamlessly connects data, technology, processes, and
multi-functional expertise, and is designed to foster close
collaboration with all constituents.”
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology and medical
device industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, and
reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the integrated
clinical development and regulatory information management process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 86
locations in 51 countries around the world, and had approximately
19,370 employees in the third quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
1 KMR Group - Clinical Group, 2015
2 KMR Group - Clinical Group, 2015
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170619005601/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comorKathryn McMahon, PAN CommunicationsTel: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1-781-434-4753Email: ron.aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2023 to Mar 2024